Skip to main content
Clinical Trials/NCT01983371
NCT01983371
Withdrawn
Not Applicable

Diagnostic Accuracy of Ferumoxytol-Enhanced MRI for Detecting Lymph Node Metastases in Colorectal Cancer

Scott Potenta, MD, PhD1 site in 1 countryStarted: December 2013Last updated:

Overview

Phase
Not Applicable
Status
Withdrawn
Sponsor
Scott Potenta, MD, PhD
Locations
1
Primary Endpoint
Prospectively evaluate the diagnostic accuracy of ferumoxytol-enhanced MRI in the setting of colorectal cancer with histopathologic analysis as the gold standard.

Overview

Brief Summary

The purpose of this study is to determine the diagnostic accuracy of ferumoxytol-enhanced MRI in detecting lymph nodes that have been invaded by tumor cells in patients with colorectal cancer.

Detailed Description

This study will investigate the accuracy of ferumoxytol-enhanced MRI in detecting lymph nodes that have been invaded by tumor cells in patients with colorectal cancer. This study will be performed in addition to any ongoing routine care and will not serve as a substitute for any imaging tests that would be routinely performed prior to surgery.

Study Design

Study Type
Interventional
Allocation
Na
Intervention Model
Single Group
Primary Purpose
Diagnostic
Masking
None

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Patients 18 years of age or older with histologically confirmed colorectal cancer
  • Planned for surgical resection of tumor

Exclusion Criteria

  • Contraindications for MRI
  • Contraindication or known allergy to ferumoxytol or parental iron products (e.g. iron sucrose, iron dextran, etc.)
  • Planned chemotherapy or radiation treatment prior to surgical resection of primary tumor
  • Uncontrolled serious medical illness
  • Unable or unwilling to give informed consent
  • Pregnancy
  • Breastfeeding women
  • Clinically documented or known risk of primary or secondary iron overloading including history of thalassemia, sickle cell anemia, hereditary hemochromatosis or first-degree relative with known hemochromatosis, multiple transfusions for any reason within the past 5 years, or use of over-the-counter ferrous sulfate without the supervision of his/her doctor

Arms & Interventions

Ferumoxytol-enhanced MRI

Experimental

This is a single-arm study. All enrolled patients will have a ferumoxytol-enhanced MRI scan.

Intervention: Ferumoxytol (Drug)

Ferumoxytol-enhanced MRI

Experimental

This is a single-arm study. All enrolled patients will have a ferumoxytol-enhanced MRI scan.

Intervention: Magnetic Resonance Imaging (Other)

Outcomes

Primary Outcomes

Prospectively evaluate the diagnostic accuracy of ferumoxytol-enhanced MRI in the setting of colorectal cancer with histopathologic analysis as the gold standard.

Time Frame: 3 years

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor
Scott Potenta, MD, PhD
Sponsor Class
Other
Responsible Party
Sponsor Investigator
Principal Investigator

Scott Potenta, MD, PhD

Clinical Instructor

University of Vermont

Study Sites (1)

Loading locations...

Similar Trials